Recent research suggests a possible increased risk of serious eye conditions, such as non-arteritic anterior ischaemic optic ...

A popular drug used for diabetes and weight loss may also help protect the brain. That’s the key message from a new study ...

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...

Semaglutide is the active ingredient in the weight loss medication Wegovy and the diabetes drugs Ozempic and Rybelsus, which ...

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and ...

NAION is the second most frequent cause of vision loss due to optic nerve damage, with advanced age and long-standing type 2 ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Semaglutide, a GLP-1 receptor agonist, has already shown benefits for weight loss and cardiovascular health. This new study adds to growing evidence that the drug’s effects may extend to ...

A study has found that prescribing semaglutide in everyday clinical settings led to modest but meaningful improvements in cardiovascular risk alongside a rise in non-drug healthcare costs. The study, ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.